-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, the data released by miR Scientific at the annual meeting of the American Urological Association (AUA) showed that its technology of using urine to detect prostate cancer can accurately detect prostate cancer at the molecular level and its risks Classification
.
The detection technology only requires a urine sample, and the prediction accuracy rate exceeds 90%
.
This prostate cancer detection technology, called miR Sentinel, has been certified by the FDA as a breakthrough medical device.
It is a non-invasive molecular test based on the analysis of small non-coding RNA (sncRNA) in exosomes in urine
.
It provides an innovative method to analyze the sncRNAs of urine samples.
Using the expression patterns of these sncRNAs, a score is obtained through a proprietary statistical classification algorithm, which can classify patients into four categories: no molecular evidence of prostate cancer ; Low-risk; medium-risk; or high-risk prostate cancer
.
Image source: miR Scientific's official website.
When comparing the results of miR Sentinel detection technology and systemic biopsy among men who were initially suspected of prostate cancer, the study showed that the consistency of the two screening and detection methods in the classification of clinically significant cancers was 93%
.
The data further proved that the miR Sentinel test correctly identified 96% (371/387) of men with non-clinically significant cancer
.
Mr.
Sam Salman, Chairman and CEO of miR Scientific, said: “Our mission to transform cancer management has been further validated in this prospective study, proving that miR Sentinel prostate cancer test can provide an accurate non-invasive method in the organization.
Before the biopsy, identify whether there is any prostate cancer and classify the risk of metastasis
.
We believe that the accuracy, accessibility and non-invasive features of this technology will affect the lives of millions of men and change urological cancer The standard of care
.
"Reference: [1] miR Scientific Presents Groundbreaking Data on the Exceptional Accuracy of its Prostate Cancer Liquid-Biopsy Test.
Retrieved September 20, 2021, from https:// mir-scientific-presents-groundbreaking-data-on-the-exceptional-accuracy-of-its-prostate-cancer-liquid-biopsy-test-301380193.
html?tc=eml_cleartime Disclaimer: WuXi AppTec's content team focuses on introducing the world Progress in biomedical health research
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.